Redhill Biopharma Ltd. (RDHL) - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on June 12, 2023, incorporates a press release detailing Redhill Biopharma Ltd.'s financial results and operational highlights for the first quarter ended March 31, 2023. The period was defined by a strategic pivot following the divestiture of the Movantik business to extinguish debt obligations, shifting focus to the commercialization of Talicia and the development of pipeline assets including opaganib and RHB-107.
Key Financial Metrics
| Metric | Q1 2023 | Q4 2022 |
|---|---|---|
| Net Revenues | $3.6 million | $12.8 million |
| Talicia Net Revenues | $3.4 million | $2.2 million |
| Gross Profit | $2.0 million | $4.2 million |
| Operating Income | $29.1 million | ($9.9 million) loss |
| Net Income | $50.2 million | ($3.7 million) loss |
| Cash Balance (as of Mar 31, 2023) | $28.8 million | N/A |
| Total Assets | $58.8 million | $158.9 million |
| Total Liabilities | $56.8 million | $207.3 million |
| Debt Obligations | $0 (Extinguished) | $115.2 million |
Note: Net Income and Operating Income were significantly driven by non-cash gains related to the Movantik divestiture and debt extinguishment.
Material Changes vs. Prior Period
- Revenue Decline: Total net revenues decreased 72% from Q4 2022 due to the cessation of Movantik revenue recognition on February 2, 2023. Talicia revenues increased 55% quarter-over-quarter due to a 20% increase in units sold.
- Debt Extinguishment: All debt obligations under the Credit Agreement with HCR Collateral Management LLC were extinguished in exchange for the transfer of Movantik rights. This resulted in a $21.2 million financial income gain.
- Asset and Liability Reduction: Total assets decreased by $100.1 million and total liabilities decreased by $150.5 million, primarily due to the transfer of Movantik rights and the assumption of liabilities by the buyer.
- Cost Reduction: Selling, Marketing, and General and Administrative expenses decreased to $10.9 million from $13.0 million due to ongoing cost-reduction measures.
Guidance, Outlook, and Risks
Operational Highlights:
- Opaganib: Selected by the NIH for a product development contract for Acute Radiation Syndrome (ARS). FDA guidance received on using the Animal Rule for development.
- RHB-107: Development for outpatient COVID-19 prioritized with potential non-dilutive funding. Resources redirected from the terminated RHB-204 study.
- RHB-204: Phase 3 study for NTM disease terminated due to low accrual rates.
- Talicia: Launched a warranty program to reimburse patients if the treatment fails; coverage exceeds 202 million lives.
Capital Markets and Risks:
- Nasdaq Compliance: The Company received notice of non-compliance with the minimum Market Value of Publicly Held Shares (MVPHS) requirement ($15 million) as of May 9, 2023. It has 180 days (until November 6, 2023) to regain compliance or face delisting.
- Financing: Closed a $6 million registered direct offering on April 3, 2023. The Company expects to recognize a $1.1 million financial expense in Q2 2023 related to warrant fair value.
- Litigation: Continuing litigation against Kukbo Co. Ltd. regarding a $6.5 million default on a subscription agreement.
Investor Verification Checklist
- Verify the timeline and conditions for regaining Nasdaq MVPHS compliance to avoid delisting.
- Confirm the status of non-dilutive funding discussions for RHB-107 and Opaganib.
- Monitor the progress of the Kukbo Co. Ltd. litigation and potential recovery of the $6.5 million claim.
- Review the impact of the $1.1 million expected financial expense in Q2 2023 on future earnings.
- Assess the commercial performance of Talicia in the absence of Movantik revenue.